The analgesic effect and safety of parecoxib sodium in patients after renal transplantation was studied. Forty-eight patients undergoing renal transplantation were recruited and randomly assigned to three groups (n = 16): Control (2 ml normal saline), parecoxib sodium treatment (40 mg) and fentanyl treatment (0.1 mg). Hemodynamic parameters were recorded prior to, at the time of, or after extubation. The visual analogue scale/ score (VAS), Ramsay sedation score, blood urea nitrogen (BUN) and serum creatinine levels were recorded. No significant differences for age, gender, weight, length of hospitalization, operation time or intraoperative infusion volume among the three groups (P > 0.05). There were no significant differences (P > 0.05) over time in values of hemodynamic parameters, in the parecoxib sodium treatment group. Parecoxib sodium efficiently improved postoperative analgesia, decreased the incidence of side effects and reduced the number of patients treated with drugs for postoperative analgesia. Parecoxib sodium administration provides stable hemodynamics, improves postoperative conditions and decreases the incidence of side effects in patients receiving renal transplantation without any adverse effects on renal function. Parecoxib sodium might be a candidate drug for postoperative pain relief in patients with renal transplantation.
[1]Jilin Univ, Dept Anesthesiol, Hosp 1, Changchun, Jilin, Peoples R China.
[2]Jilin Univ, Dept Urol, Hosp 1, Changchun, Jilin, Peoples R China.
(8.0+极速模式)